The AND gate functions such that when all inputs are activated the downstream gene will be transcribed and it is off otherwise. To accomplish optimal and targeted gene therapy in solid tumor patients, we have constructed an AND gate genetic circuit and investigated whether it could be activated by low-dose radiation in vitro and in vivo. The enhancement green fluorescent protein (EGFP) expression in different tumor cells transfected with control vector plxsn-EGFP confirmed that 2 Gy of radiation and 1% O 2 for 3 h could activate our AND gate. Besides, the obvious different levels of EGFP expression between 2 and 6 Gy of radiation demonstrated that the AND gate could be regulated by radiation doses. Additionally, through EGFP expression and the codistribution of p53 and HIF-1a in xenografts, we illustrated the targeted activation property of the AND gate and real-time monitoring to hypoxic districts in vivo. Moreover, significant growth inhibition and cell cycle arrest in vitro and apoptosis-inducing effects in vitro and in vivo proved that the AND gate induced ideal antitumor effects. In conclusion, the radiation dose-regulated AND gate genetic circuit could not only effectively monitor the therapeutic process in real-time but also induce ideal antitumor efficacy, and can be further exploited for personal therapy in clinical tumor patients.
INTRODUCTION
Cancer is a leading cause of death worldwide today.
1 Although significant advances have been made in the prophylaxis of tumorigenesis and treatment of cancer, the morbidity and mortality of malignant tumors remain high. Conventional treatments, such as radical-surgical resection, chemotherapy and radiotherapy, have shown good efficiency in most malignant neoplasms, but still result in failure to cure nearly 50% of cancer patients. 2 The poor survival is mainly due to individual differences, chemo-radio-therapy resistance and unacceptable degree of toxicity to normal tissues induced by chemotherapeutic agents and ionizing radiation (IR). 3, 4 Tumors often show the characteristics of recurrence, invasiveness and metastasis, which make them more complicated. 5 --7 Therefore, novel approaches that can kill tumor cells selectively, effectively and safely are ideal treatments for cancer and can be further explored to improve the prognosis of cancer patients in the clinic.
Since the first human clinical trials provided initial evidence of the feasibility and safety of administration of recombinant DNA sequences, many different diseases are being investigated as candidates for gene therapy, especially malignant tumors. 8 Hypoxia and radiation sensitivity are particular characteristics in numerous solid human tumors that can be exploited for selective cancer therapy. 9, 10 By combining the two characteristics, we previously devised a special AND gate vector by connecting the radiation-responsive promoter cArG 6 to the heat shock response signal elements SNF1, heat shock factor-1 and heat shock element ( Figure 1 ). This AND gate genetic circuit has been demonstrated to be activated by 6 Gy of radiation and 1% O 2 treatments together but not alone, and to regulate the therapeutic gene p53 expression in hypoxic tumor cells receiving radiation, instead of peritumoral and other hypoxic normal cells in vitro and in vivo. This designed strategy can effectively avoid normal tissue toxicity, and make selective targeted therapy possible. However, tumors vary in their responses to IR, and even tumors from the same histological group can also present with extremely heterogeneous radiosensitivity. 11 Moreover, because the growth of most malignant tumors shows irregular patterns, and some tumors are closely linked with vital organs such as the brain, kidney or nerve, the clinical-treatment dose of radiation should be attenuated to reduce the damage to normal tissues. Therefore, the effect of this AND gate may be weakened by different degrees. Thus, if the AND gate can be activated by low-dose radiation and regulated by radiation doses, we can apply it in most solid tumors by regulating the stimuli dose, according to the tumor location and radiation sensitivity.
On the other hand, the radiation resistance of hypoxic tumor cells is two to three times higher than that of oxygenic tumor cells, 12 and hypoxia not only provides an environment directly facilitating chemo-and radio-resistance, but also encourages the evolution of phenotypic changes and further induces permanent resistance to treatment. 13 Hence, if our AND gate can be developed as a sensitive, reproducible and noninvasive method to monitor the distributional characteristics of tumor hypoxia, realtime assessment of the therapeutic process targeting highly resistant tumor cells can be accomplished and resistance induced by hypoxia can also be overcome.
Based on the above analysis, we planned to explore the radiation dose-regulated characteristic of the AND gate and monitor its therapeutic response to hypoxic tumors. This strategy can not only indicate hypoxic tumor tissues, regardless of their superficial, interior or irregular features, but also accomplish effective targeted effects to tumor cells that receive low-dose radiation.
The application of combined radiation and hypoxia for cancer gene therapy has been reported elsewhere; 14 --16 for example, Greco et al.
14 constructed recombinant plasmids, including early growth response gene-1 (Egr-1) and hypoxia response element (HRE) as dual-sensitive promoters, that could drive herpes simplex virus-thymidine kinase (HSV-TK) suicide gene expression. This strategy was more efficient than using an Egr1 or HRE promoter separately, under the conditions of radiation and hypoxia. However, these methods that can be activated by either hypoxia or radiation, or combined stimuli exhibit relatively low-targeted property and induce damage to normal tissues for the expression of suicide gene. Furthermore, this strategy cannot monitor the hypoxic environment and the therapeutic response in malignant tumors in real time, so the clinical application may be hindered. Hence, utilizing radiation therapy and hypoxia to monitor the hypoxic areas of tumor tissues and to guarantee targeted expression of suicide genes is a novel strategy of gene therapy and has not yet been reported.
In the present study, we transfected different tumor cell lines with the constructed AND gate vectors to verify that the AND gate genetic circuit could be activated by 2 Gy of radiation and 1% O 2 for 3 h. In vitro and in vivo experiments were conducted to analyze the dynamic processes of exogenous gene expression in real time, which represented the therapeutic response to non-small-cell lung carcinoma. The results demonstrated that the AND gate could be regulated by different radiation doses and the activated AND gate could induce significant growth inhibition and tumor eradication effects even under a low level of radiation stimulus. The coexpression of wtp53 and HIF-1a also implied that the AND gate could be used for noninvasive and real-time monitoring of hypoxic areas. The current study creates a real-time method to monitor tumor-targeted therapy and provides a new gene therapy for personalized treatment of most solid tumor patients.
MATERIALS AND METHODS

Plasmids and reagents
Retroviral vectors plxsn-EGFP (enhancement green fluorescent protein) and plxsn-wtp53 were constructed as shown in Figure 1b of our previous work (unpublished). cArG 6 promoter and HSE 4 reporter were synthesized by utilizing complementary oligodeoxyribonucleotides reannealing technology (Sangon Company, Shanghai, China) and subcloned into transcriptional control subsequences in the 5 0 -LTR sequence of plxsn. SNF1, heat shock factor-1, EGFP and wild-type p53 (wtp53) genes were generated by proofreading PCR. SNF1 and heat shock factor-1 complementary DNA (cDNA) sequences were inserted into the downstream region of cArG 6 and EGFP was inserted into the downstream region of heat shock element. This yielded the plasmid named plxsn-EGFP. The vector plxsn-EGFP, which was able to express EGFP under optimized stimuli, was used as a nontherapeutic, monitoring control vector. The therapeutic vector plxsn-wtp53 was constructed by replacing EGFP with wtp53 gene in the control vector. All plasmids were identified through enzyme digestion and verified by sequencing.
Cell lines and cell culture
The following five human cell lines were purchased from the American Type Tissue Culture Collection (ATCC, Manassas, VA): the non-small-cell lung carcinoma A549 cell lines, cervical cancer HeLa cells, hepatocellular carcinoma HepG2 cells, breast carcinoma MCF-7 cells and human embryonic kidney 293 cell lines. A549 and 293 cells were maintained in RPMI-1640 culture media (Gibco, Gaithersburg, MD) and HeLa, HepG2 and MCF-7 cells were cultured in high-glucose DMEM complete culture media (Gibco). All the media contained 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Sigma, St Louis, MO). All the cells were cultured in a well-humidified incubator with 5% CO 2 at 37 1C and tested regularly for the presence of mycoplasma.
Transient transfection and radiation-hypoxia intervention For experiments under radiation and hypoxia intervention, transfected A549 cells were exposed to 2 Gy of radiation emitted by a Pantak PCM 1000 X-ray generator (Pantak, East Haven, CT), then placed in a hypoxia incubator with 1% O 2 , 94% N 2 and 5% CO 2 for 3 h, and finally returned to a normal homeothermic incubator. Then, cells were collected and counted with a cytometer (Beckman Coulter, Hialeah, FL) for the following experiments. Figure 1 . Genetic logic gates. (a) Logic gates: In AND gate, when the activator and inducer are activated simultaneously, the downstream gene is expressed as the output; otherwise it is in off position. In contrast to the AND gate, in OR gate circuit, either the activator or the inducer can lead to the expression of output gene. (b) AND gate based on heat shock response elements SNF1, heat shock factor-1 (HSF1), heat shock element (HSE 4 ) and radiation response promoter cArG 6 . In this AND gate, when cArG 6 and hypoxia are activated simultaneously, downstream EGFP or p53 gene will be induced to express.
RNA extraction and reverse transcription (RT)-PCR analysis
Total RNA was extracted by using the Trizol reagent (Invitrogen). cDNA was synthesized with the PrimeScript RT reagent Kit (TaKaRa, Shuzo, Kyoto, Japan). One microliter of cDNA was used as a template for the PCR reaction. PCR was performed in 50 ml of buffer containing 5 ml of 10 Â PCR buffer, 4 ml of MgCl 2 , 4 ml of dNTPs, 1 ml of each primer, 0.25 ml of Taq DNA polymerase and 35.75 ml of sterilized water for 42 cycles of denaturation at 94 1C for 1 min, annealing at 52.5 1C for 1 min and extension at 72 1C for 2 min. The primer sequences were as follows: GAPDH forward:
Western-blotting analysis A549 cells were lysed in 80 ml of ice-cold lysis buffer (Roche Diagnostics, Indianapolis, IN) for 40 min. Protein concentrations were measured through Bradford methods (Bio-Rad, Hercules, CA) according to the manufacturer's instructions, and equal amounts of total proteins were loaded to 12% SDS-PAGE, electrophoresed at 120 V for 1.5 h and then transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA) using a semi-dry method (Bio-Rad) at 1 mA cm À2 for 60 min. The membranes were blocked with 5% skimmed milk in TBST buffer (0.1% Tween 20 in TBS) for 2 h at 37 1C, then incubated with primary antibodies overnight at 4 1C, washed three times with TBST for 15 min each and then incubated with secondary antibodies with 5% skimmed milk in TBST for 1 h at 37 1C. Finally, the proteins were detected using the ECL protocol (Beyotime Institute of Biotechnology, Jiangsu, China) and then scanned and analyzed by the automatic image analyzer. GAPDH was used as control. p53 primary antibody was obtained from Cell Signaling (Fremont, CA). BAX, BCL-2 and GAPDH primary antibodies and all the secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Assays for cell cycle, apoptosis and proliferation
For cell cycle detection, the same amount of A549 cells was harvested and fixed in 1 ml of 75% ethanol at 4 1C overnight, followed by incubation with RNase (Sigma) for 30 min at 37 1C and propidium iodide (PI, Invitrogen) for 1 h later. Then, detection was measured by flow cytometry with a FACS-Calibur (Becton Dickenson, San Jose, CA).
To detect cellular apoptosis, cells were trypsinized and about 5 Â 10 (n ¼ 5 mice per group): the normal group (xenografts without treatment); the radiation group (xenografts receiving 2 Gy of radiation only); the EGFP group (xenografts receiving plxsn-EGFP plasmids injection only); the wtp53 group (xenografts receiving plxsn-wtp53 plasmids injection only); the EGFP þ R group (xenografts receiving plxsn-EGFP plasmids injection þ radiation); the wtp53 þ R group (xenografts receiving plxsnwtp53 plasmids injection þ radiation). All the animals were killed 3 days after the treatment. Xenografts were dissected free from surrounding normal tissues and fixed with 4% paraformaldehyde.
Histological analysis
Tissue arrays were performed on 5 mm sections of paraffin embedded and stained with hematoxylin-eosin (H&E) for detection of apoptotic cancerbearing cells.
Immunohistochemical (IHC) staining
Immnohistochemical detection of EGFP and wtp53 proteins was performed on paraffin section. First, endogenous peroxidase activity was blocked by 0. 
Detection of apoptosis in xenografts
Sections were fixed in 4% paraformaldehyde, permeabilized in methanol and stained using TdT-mediated dUTP nick end-labeling (TUNEL) reaction mixture. Apoptotic cells on the paraffin-embedded sections were determined using an in situ cell death detection kit (Roche) according to the manufacturer's instructions.
Immunofluorescence double staining Double staining for HIF-1a and p53 expression in xenografts was performed by immunofluorescence. Sections were washed in PBS and blocked with 5% NGS for 30 min in a moist chamber at 37 1C, then incubated with an anti-HIF-1a primary antibody (Millipore), which was diluted 1:200 at 4 1C overnight, and a secondary antibody conjugated with FITC (Invitrogen), which was diluted into 1:100 in PBS with 5% NGS at 37 1C wtp53 group at 24 h; 5: normal group at 48 h; 6: control group at 48 h; 7: wtp53 group at 48 h; 8: normal group at 72 h; 9: control group at 72 h; 10: wtp53 group at 72 h. wtp53 group compared with the normal group: **Po0.01; wtp53 group compared with the control group: for 1 h. Subsequently, the slides were incubated with anti-p53 primary antibody (Santa Cruz) diluted 1:200 at 4 1C overnight and an appropriate secondary antibody that was conjugated with TITC (Santa Cruz). Then, sections were stained with 4,6-diamidino-2-phenylindole (DAPI, Beyotime) and coverslipped with an antifade solution. At last, stains were evaluated using a confocal laser scanning microscope (Leica TCS SP2, Leica Microsystems, Wetzlar, Germany).
Statistical analysis
Significance tests were conducted using SPSS 13.0 software, followed by pairwise comparison between specific groups (Student's t test). Data were expressed as the average ± s.e.m. of the indicated number of determinations. The statistically significant difference was assigned as Po0.05.
RESULTS
Identification of the activation of the synthetic AND gate
To select the proper radiation dose and to evaluate the lethal effects of radiation, we detected the apoptosis proportion of 293 and A549 cells receiving different radiation dose treatments. As shown in Figure 2a , 293 and A549 cells showed a lower apoptosis level under 2 Gy of radiation as compared with other radiation doses. Therefore, we chose 2 Gy as the stimulus dose, and tested whether it could initiate our constructed AND gate gene circuit. Additionally, we could also see that the tumor cells were more resistant to radiation and hypoxia increased the ability, whereas the opposite role was shown in 293 cells. To test whether the vectors could be activated by 2 Gy of radiation and 1% O 2 for 3 h, A549 cells were transiently transfected with plxsn-EGFP vectors and treated with either or both radiation and hypoxia stimuli and the activity of the vectors was assessed by relative EGFP fluorescence. From Figures 2b and c , it can be seen that EGFP was expressed only at a low level in transfected cells receiving radiation and hypoxia instead of other treatments at 24 h, but its expression level was apparently elevated at 48 h and persisted at 72 h.
To confirm whether the AND gate can be regulated by radiation doses, we further measured the EGFP expression rate in A549 cells receiving different doses of radiation at 48 h. As shown in Figure 2d , EGFP level varied in a radiation dose-dependent manner. The EGFP protein exhibited a lower level in A549 cells receiving 2 Gy than in those receiving 6 Gy but was also expressed in nearly 25% of tumor cells.
Therefore, although 2 Gy induced a relatively low level of downstream gene expression, it also induced little damage to the normal cells. With high EGFP expression and normal tissue safety, 2 Gy could be the proper stimulus of the AND gate genetic circuit. Additionally, 2 Gy is also the basic treatment dose of radiation therapy in clinic.
Activation and expression of therapeutic AND gate in A549 cells
From the bright fields of A549 cells (Figure 3a) , we could observe that plxsn-wtp53 vector-transfected cells receiving 2 Gy of radiation and hypoxia treatments showed significant growth inhibition and apoptosis promotion, such as obvious intercellular space and decreasing numbers of cells. However, cells in the normal and control groups displayed no obvious morphological changes. Hence, we concluded that the AND gate was activated by radiation and hypoxia treatments and produced antitumor effect. The expression of the AND gate vectors was further confirmed through wtp53 expression at the transcriptional and posttranscriptional levels in A549 cells. As shown in Figure 3b , in the wtp53 group, p53-mRNA expression, which was detected by RT-PCR, was lower at 24 h but much higher at 48 h (Po0.01) and 72 h (Po0.01) compared with that in the normal and control groups. A similar expression of wtp53 protein was detected by western blotting. As shown in Figure 3c , wtp53 protein showed much higher levels at 48 h (Po0.01) and 72 h (Po0.01) in the wtp53 group, compared with no obvious expression in the normal and control groups. The reason for the absence of the wtp53 band in the wtp53 group at 24 h might be the low expression level of p53 that could not be detected.
These findings agreed with the characteristics of the AND gate and verified that our devised genetic circuit could be activated by 2 Gy of radiation and 1% O 2 and promote the downstream gene expression at transcriptional and translational levels.
Antitumor efficacy of activated wtp53 in vitro
The antitumor effects of the activated AND gate were assessed through cell cycle, apoptosis and proliferation detection. The results were the cells in the wtp53 group displaying G1-G2 phase arrest at 48 h (Figure 4a ), significant apoptosis promotion at 24, 48 and 72 h (Po0.01) (Figure 4b ) and a lower proliferation velocity at 24 h and 48 h (Po0.05) (Figure 4c ). In addition, the expression of apoptosis-related proteins BAX (proapoptotic protein) and BCL-2 (prosurvival protein) were measured in transfected A549 cells after radiation and hypoxia treatments at 48 h. Higher levels of BAX protein (Po0.01) and lower levels of BCL-2 protein (Po0.01) were detected in the wtp53 group, compared with normal and control groups (Figure 4d ).
All these results implied that the activated AND gate could produce a marked effect of inhibiting cell mitosis and proliferation, and promoting cell apoptosis, and the data were also in accordance with the results of our previous experiments.
Distribution of the AND gate in vivo A549 cells were injected into athymic nude mice subcutaneously, plxsn-EGFP plasmids were injected into xenografts at 13 days, and 2 Gy of focal radiation was given at 14 days. Three days later, all animals were killed, and xenografts were harvested for the following experiments. To evaluate the efficacy of the activated AND gate, we further monitored the distribution of plxsn-EGFP plasmids in A549 xenografts. Remarkably, we found the activated AND gate marker EGFP was only preferentially expressed in xenografts of plxsn-EGFP injection and receiving 2 Gy of radiation ( Figure 5 ). The results indicated that the AND gate could be activated in vivo and also implied the existence of hypoxic districts in A549 xenografts.
The tumor suppression effect of activated AND gate in A549-bearing mice Apoptosis in situ and wtp53 expression were detected to testify the suicide effect of the therapeutic vectors. As shown in Figure 6 , cells of xenografts receiving plxsn-wtp53 injection and 2 Gy of radiation showed significant apoptosis behaviors, such as karyopyknosis, bubbles in cytoplasm and obvious apoptotic bodies. Slight apoptotic changes also could be observed in xenografts receiving radiation compared with normal and control Figure 6 . H&E staining of A549 xenografts. Normal: A549 xenografts without treatment; radiation: A549 xenografts receiving 2 Gy of radiation; wtp53: A549 xenografts receiving plxsn-wtp53 plasmid injection; wtp53 þ R: A549 xenografts receiving plxsn-wtp53 plasmid injection and 2 Gy of radiation.
groups. Apoptosis in situ and wtp53 expression were also detected to testify the suicide effect of the therapeutic vectors. Upon immunohistochemical staining analysis, prominent positive apoptotic cells appeared in xenografts receiving plxsnwtp53 injection and 2 Gy of radiation (Figure 7a) . Moreover, wtp53 protein was detected to be located in nuclear envelopes and the perinuclear space and exhibited a higher level of expression in the wtp53 þ R group than in other treatment groups (Figure 7b ). The significant results implied that the activated AND gate could lead to expression of downstream gene wtp53 and further induce the apoptosis of tumor cells, which were consistent with the experiments in vitro and also suggested that radiation could induce endogenic p53 expression in tumor cells.
The codistribution of activated AND gate in hypoxic districts in vivo Although wtp53 protein was detected in vivo, its expression in hypoxic tumor districts receiving radiation was not confirmed. We verified the expression of HIF-1a/wtp53 through immunofluorescence double staining. HIF-1a protein, an important hypoxic marker, could be detected in all A549 xenografts regardless of their receiving the radiation treatment or not, and there was no discernible difference in the amount and specificity among different groups. But the wtp53 protein showed different expression. wtp53 protein was detected to specifically express in HIF-1a-positive cells of xenografts receiving 2 Gy of radiation instead of other groups (Figure 8 ). The data implied that radiation and hypoxia initiated the AND gate together and the downstream gene of AND gate was specially expressed in hypoxic areas.
Moreover, the AND gate could also be used to monitor the hypoxic cells in A549 xenografts.
Identification of the activation of the synthetic AND gate in HeLa, HepG2 and MCF-7 cells To further test whether the AND gate could be activated in other tumor cells or not, HeLa, HepG2 and MCF-7 cells were transiently transfected with plxsn-EGFP vectors and then treated with 2 Gy of radiation or 1% O 2 , or both. As shown in Figure 9 , EGFP was expressed only in cells receiving radiation and hypoxia and not in cells receiving other treatments at 48 h. The results were consistent with the EGFP expression in A549 cells (Figure 2b ) and further supported that our AND gate could be activated by radiation and hypoxia stimuli in other solid tumor cell lines.
DISCUSSION
The intolerance of peritumoral normal tissues to IR inhibits the application of high radiation doses for cancer patients and reasonably leads to unsuccessful treatment and local recurrence of malignant tumors. 17, 18 Improved physical targeted radiation, such as three-dimensional external beam conformal radiotherapy and intensity-modulated RT, has enabled more precise dose delivery to tumor masses, while limiting the exposure of surrounding normal tissues. 19, 20 Nevertheless, the treatment of certain malignancies remains problematic, as malignant tumors are a type of complicated disease that involves the activation and inactivation of different oncogenes during the process of tumorigenesis. 21 With respect to its efficiency and safety, gene therapy, introduced in the late 1970s after the development of Figure 7 . Influence of the activated AND gate on A549 xenografts. Immunohistochemical detection of apoptosis in situ (a) and p53 (b) in tumor-bearing sections. Normal: A549 xenografts without treatment; radiation: A549 xenografts receiving 2 Gy of radiation; wtp53: A549 xenografts receiving plxsn-wtp53 plasmid injection; wtp53 þ R: A549 xenografts receiving plxsn-wtp53 plasmid injection and 2 Gy of radiation. wtp53+R group compared with normal group: **Po0.01; wtp53+R group compared with control groups: recombinant DNA technology, has emerged as a new and optimal choice in different types of tumors. 8, 15, 22 However, the location of gene expression in target tissue remains a major problem in clinical trials because the success of gene therapy depends primarily on the specific accumulation of therapeutic genes to the target tissue. Therefore, in our experiments, we constructed an AND gate genetic circuit that could be particularly activated in hypoxic tumor cells of the radiation field. This strategy can guarantee that the therapeutic gene is expressed only in hypoxic tumor cells and not in normal tissues. The expression of EGFP in vitro and the coexpression of HIF-1a and wtp53 in vivo demonstrated the specific and targeted expression of our AND gate gene circuit. The activated AND gate showed marked antitumor activity in vitro and in vivo. Additionally, the significant result that the recombinant AND gate could be activated by low-dose IR and a short period of hypoxia suggests that this AND gate can be used in tumors with low tolerance to radiation and minor hypoxia.
In our previous research, we demonstrated that the AND gate could be activated by 6 Gy of radiation and 1% O 2 in vitro and in vivo. On combining the data from the present study, we can see that the AND gate can be regulated by different radiation doses (4 Gy, not shown). Thus, we conclude that the AND gate can be used in most hypoxic solid tumors by selecting the appropriate dose of radiation. That is to say, if the peritumoral normal tissues are radiosensitive, we can cut down the radiation dose and otherwise heighten the dose. Furthermore, from our apoptosis screening for radiation doses, we can infer that 2 Gy of radiation actually induces less damage to normal cells. Hence, we can achieve better antitumor effects with the targeted gene therapy compared to our previous research. Figure 8 . Immunofluorescence double staining of HIF-1a (green) and p53 (red) expression in A549 xenografts at 17 days by confocal microscopy. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) (blue) for background. Normal: A549 xenografts without treatment; radiation: A549 xenografts receiving 2 Gy of radiation; wtp53: A549 xenografts receiving plxsn-wtp53 plasmid injection; wtp53 þ R: A549 xenografts receiving plxsn-wtp53 plasmid injection and 2 Gy of radiation.
Hypoxia, a significant adverse factor for cancer prognosis, has been shown to adversely affect locoregional control and/or disease-free survival after surgery, radiotherapy and chemotherapy. 23, 24 Current knowledge provides very little information about the biodistribution of hypoxic areas and the temporal and spatial expression of the therapeutic gene in hypoxic cells. Therefore, noninvasive and clinically applicable monitoring techniques for gene therapy are the urgent needs. In our study, the in vitro experiment showed that the EGFP protein was particularly expressed in partial hypoxic tumor cells receiving radiation and this result was further seen in nude mice. All data show that the control vector plxsn-EGFP can be used as a sensitive, reproducible and noninvasive monitor of hypoxic cells in human malignant tumors and provides real-time assessment of the efficacy of therapeutic regimens such as IR and chemical therapy. Besides, the AND gate can also be used to treat the hypoxic tumor stem cells, which might be the radical cause of tumor recurrence and metastasis.
The efficacy of therapeutic gene expression is a subject of focus in targeted gene therapy. Compared with the low-level expression of the transfection plasmids that are observed in other reports, 25 in our experiments, we utilized radiation response element as the promoter, which was identified to induce downstream gene expression strongly under radiation. The results also demonstrated that the constructed chimeric radiation promoter, cArG 6 , induced relatively high p53 protein expression in human non-small-cell lung carcinoma cell lines. Additionally, prominent growth inhibition and apoptosis rate in vitro and in vivo also proved that the AND gate could induce ideal lethal efficiency to tumor cells.
The gene transfer systems are another critical factor for successful suicide gene therapy. Although we supply an ideal and novel cancer gene therapy strategy for clinical application, the low level of wtp53 expression and apoptosis rate of A549 cells in in vivo experiments implies that the route of administration that can make the AND gate plasmids accumulate into the tumor mass and produce a marked lethal effect remains to be exploited. Currently, gene therapy carriers, including monoclonal antibodies, virus or plasmid vectors, 26 are often used through venous or local injections. But these methods, especially virus vectors, inevitably induce some side effects, such as low infection efficacy, mutation or apoptosis of normal cells. 27 For example, most adenoviruses cannot infect nondividing cells, such as cancer stem cells, which are a possible target of gene therapy. 28 Ideal carriers should possess the following characteristics: good targeted ability, no or low toxicity, easy detection and so on. Methods of delivering our therapeutic vectors into tumor masses will be the focus of our future research.
Another problem is the long-term expression of the target gene. In our study, we observed the killing effectiveness of activated AND gate vectors only at 3 days in vivo; long-term lethal effects will be screened in the future.
In this constructed gene circuit, the initiating stimulus of radiation can be replaced by other treatments. For example, cArG sequences can also be activated by cisplatin, 29 which is a commonly used chemotherapeutic agent. By stimulating the production of reactive oxygen intermediates, which can activate the Egr-1 promoter by H 2 O 2 , 30 cisplatin can activate this AND gate as a substitute for radiation. Moreover, we can further exploit other stimuli for our AND gate and this idea may enlarge the application range of AND gate genetic circuits in clinical medicine.
In conclusion, our regulated AND gate, which can be activated by low-dose radiation and a short period of hypoxia, is an effective and targeted therapeutic option for patients with advanced nonsmall-cell lung carcinoma, as well as other solid tumors. This study also provides an option of a dose-regulated and real-time monitored targeted system for hypoxic tumor cells. Therefore, our constructed AND gate gene circuit can be used as an effective personalized anti-tumor strategy in future.
